Figure 6 | Scientific Reports

Figure 6

From: Combination of acamprosate and baclofen as a promising therapeutic approach for Parkinson’s disease

Figure 6

Absence of interaction between ABC and L-dopa on pharmacodynamics.

Stereotaxically-lesioned 6-OHDA rats compared to Sham-injected animals. Animals were chronically treated p.o. twice a day with ABC from D8 after lesion until D20. On D21, animals were treated with ABC +L-dopa and then akinesia tests were performed (a). (b,c) Absence of interaction between L-dopa and ABC in the initiation time and stepping tests. L-dopa was used as reference drug. 6-OHDA or ABC did not have any effect in these behavioural tests when the control ipsilateral paw was assessed in the same rats in the initiation time and stepping tests. Values are mean ± s.e.m. n = 10 per condition except for L-dopa where n = 7. *P < 0.05, **P < 0.01, ***P < 0.001 versus 6-OHDA; ANOVA with Dunnett’s test. ABC 1: ACP 0.04 mg/kg + BCL 0.6 mg/kg. L-dopa: L-dopa 8 mg/kg + benserazide 12.5 mg/kg.

Back to article page